EcoDrugPlus

Cyclin D1

Ensembl ID : ENSTMTG00000005181
Gene Symbol: CCND1
3 Cross references
280 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 1

Ensembl ID : ENSTMTG00000000127
Gene Symbol: CDK1
1 Cross references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 2

Ensembl ID : ENSTMTG00000021155
Gene Symbol: CDK2
3 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 4

Ensembl ID : ENSTMTG00000004524
Gene Symbol: CDK4
3 Cross references
237 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 6

Ensembl ID : ENSTMTG00000009854
Gene Symbol: CDK6
3 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 7

Ensembl ID : ENSTMTG00000019757
Gene Symbol: CDK7
3 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 9

Ensembl ID : ENSTMTG00000021656
Gene Symbol: CDK9
3 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSTMTG00000001590
Gene Symbol: CYSLTR1
3 Cross references
177 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytidine Deaminase

Ensembl ID : ENSTMTG00000022150
Gene Symbol: CDA
3 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 3a9-Like

Ensembl ID : ENSTMTG00000014716
Gene Symbol: LOC112115577
2 Cross references
693 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 17 Subfamily A Member 1

Ensembl ID : ENSTMTG00000003197
Gene Symbol: CYP17A1
1 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSTMTG00000023055
Gene Symbol: CYP19A1
3 Cross references
313 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).